Last update 01 Nov 2024

Lirafugratinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lirafugratinib Hydrochloride, RLY 4008, RLY-4008
+ [1]
Target
Mechanism
FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC28H24FN7O2
InChIKeyXOQVZSSDIQQUGO-UHFFFAOYSA-N
CAS Registry2549174-42-5

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
US
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
AU
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
FR
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
DE
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
HK
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
IT
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
NL
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
SG
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
KR
02 Sep 2020
Advanced Malignant Solid NeoplasmPhase 2
ES
02 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Solid tumor
FGFR2 fusions | FGFR2 amplifications | FGFR2 mutations
84
(patients with FGFR2 fusions)
jcykbqfooh(qnsdmfielw) = wsdfiqqhqz ueljzxjjdi (abewtqtzqm )
Positive
12 Oct 2023
(patients with breast cancer across all FGFR2 alterations, 10 of whom had HR+/HER2- breast cancer)
jcykbqfooh(qnsdmfielw) = estmeccnde ueljzxjjdi (abewtqtzqm )
Phase 1/2
75
(FGFRi-naïve CCA f/r)
xteifsvbbe(axqrnexdud) = 70 mg QD kfkzprsyyt (aguymndrox )
Positive
26 May 2023
(Prior-FGFRi CCA f/r)
Phase 1/2
-
-
yxwavdeprl(sakcroutrb) = vqkanlutkk idtauehrts (edahdteufd )
-
04 Apr 2023
yxwavdeprl(sakcroutrb) = xmdooxltbj idtauehrts (edahdteufd )
Phase 1/2
38
ctwmcgaqzh(kyxgzftrjr) = majority of responses ongoing wrdeixstbt (azqsghyjzv )
-
04 Dec 2022
Phase 1/2
Bile Duct Neoplasms
First line
FGFR2-fusion/FGFR2rearrangement
195
(RP2D (70 mg QD))
mlnvamacew(murhrrtvrt) = ngwratbvcy xtubopuhvu (mffivstxxl, 56.6 - 96.2)
Positive
11 Sep 2022
(All dose levels)
mlnvamacew(murhrrtvrt) = bzflbqitma xtubopuhvu (mffivstxxl, 40.8 - 73.7)
Phase 1/2
45
bzuairmdni(ctgvhutydl) = AEs occurring in >20% of pts include stomatitis (49%), palmar-plantar erythrodysesthesia (PPE, 38%), dry mouth (29%), and nail toxicities (22%), majority of which were ≤Gr 2. ezskwgjyyw (vjoeatzxyw )
Positive
01 Dec 2021
(FGFRi-naïve, FGFR2-fusion+ CCA)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free